Added to YB: 2026-10-08
Pitch date: 2026-10-04
OCUL [bullish]
Ocular Therapeutix, Inc.
+4.47%
current return
Author Info
No bio for this author
Company Info
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Market Cap
$1.6B
Pitch Price
$6.93
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.52
P/E
-5.13
EV/Sales
20.61
Sector
Pharmaceuticals
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Ocular Therapeutix, Inc.
OCUL (quick overview): Ocular Therapeutix is a potential acquisition target centered on AXPAXLI, an intravitreal axitinib implant for wet age-related macular degeneration. Its strategic appeal is the potential for longer dosing intervals that could reduce the substantial injection burden; if vision outcomes and safety are competitive, a buyer could commercialize it immediately through an established retina franchise. The risk is that a merely incremental product would not justify a strategic premium.
Read full article (1 min)